Optomed and Toku Inc. enter a partnership to commercialize AI for Cardiovascular Disease Risk
Optomed Plc Press Release 30 May 2024 at 9.00, Helsinki Optomed and Toku Inc. enter a partnership to commercialize AI for Cardiovascular Disease Risk Optomed has signed a global partnership agreement with US-based artificial intelligence company Toku Inc. Toku specializes in imaging technology and AI and has recently been granted the FDA’s Breakthrough Device designation for its cardiovascular risk detection algorithm, CLAiR. CLAiR has also achieved a CE designation, according to MDR, and a UKCA. Toku also has an AI software called BioAge for assessing a person’s biological age in